MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

UW–Madison researchers used gene therapy to prevent hereditary spastic paraplegia (HSP) in a rat model, introducing a healthy ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...